Sector News

Want international growth? Africa’s set to double pharma sales in 5 years

June 17, 2015
Life sciences
Pharma growth in China may be slowing and Europe stalling, but there’s one area where drugmakers might actually achieve some big growth, according to McKinsey & Co. That’s Africa, a mere $4.7 billion market in 2003 and $20.8 billion a decade later.
 
And now? McKinsey numbers put the African drug market at $52 billion by 2020–and as high as $65 billion on the optimistic end of things. Even at the low end of their projections–$40 billion–that’s twice the level of 2013 sales.
 
The growth drivers are familiar–and similar to other emerging markets. Africa is growing increasingly urbanized, which means better infrastructure and greater household purchasing power. Healthcare capacity is also growing, with 70,000 new hospital beds and 76,000 new doctors and nurses added between 2005 and 2012. And healthcare systems are broadening their reach beyond typical healthcare facilities. Plus, governments are increasingly supportive of the pharma business, with new rules encouraging local drug manufacturing and anticounterfeiting measures.
 
In a sense, Africa is where other emerging markets were a few years ago–and that means bigger growth potential over the next decade. “In a world of slowing and stagnating markets, Africa represents perhaps the last geographic frontier where genuinely high growth is still achievable,” the McKinsey consultants conclude.
 
The challenges of emerging markets growth apply in Africa, of course, with on-the-ground knowledge and relationships key to success. One focus for Africa-ambitious pharmas should be recruiting local sales-and-marketing talent and developing strong local managers, the report states. Also important are business partners in manufacturing and distribution–not to mention partnerships with local governments.
 
Drugmakers might want to focus on expanding city by city rather than country by country in Africa, with 37% of African consumers concentrated in just 30 cities. And it’s smart to set up capital-intensive operations in countries where governments are most stable and business regulations best developed. Outsourcing supply chains can be a good move, too, McKinsey says. And with transportation a widespread barrier, local partners are the best sources for ID’ing the most efficient ways to get products to the right place.
 
“As ever, the key to success lies in understanding individual markets in granular detail,” the report states. “Early movers with the right approach should be able to capture competitive advantage. … Now is the time for drug companies to decide whether they want to be part of that growth and, more important, play an active role in improving public health.”
 
By Tracy Staton
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”